Skip to main content

Table 2 Comparison of clinical characteristics between groups with or without residual CT abnormalities

From: One-year follow-up of chest CT findings in patients after SARS-CoV-2 infection

 

No residual legions

Presence of residual legions

 
 

(n = 19)

(n = 17)

p value

Age, years

40 (34, 54)

55 (48, 62)

0.014

Male, n (%)

22.88 (21.51, 25.15)

24.24 (23.42, 25.24)

0.318

BMI, kg/m2

11 (57.9%)

10 (58.8%)

1

Drinking history, n (%)

0 (0%)

1 (5.9%)

0.472

Current smoker, n (%)

0 (0%)

4 (23.5%)

0.04

Hypertension, n (%)

2 (10.5%)

7 (41.2%)

0.05

Type 2 diabetes, n (%)

1 (5.3%)

3 (17.6%)

0.325

COPD/emphysema, n (%)

1 (5.3%)

1 (5.9%)

0.933

Duration from illness onset to hospital admission, days

5 (2, 8)

6 (4, 7)

0.962

Severe illness during hospitalization

4 (21.1%)

8 (47.1%)

0.158

Nasopharyngeal viral RNA shedding duration, days

15 (12, 23)

19 (13, 21)

0.515

Peak CT score during hospitalization

6.5 (4, 9.5)

9 (6, 13)

0.301

Corticosteroid treatment, n (%)

11 (57.9%)

13 (76.5%)

0.302

Secondary bacterial infection, n (%)

0 (0%)

5 (29.4%)

0.016

ICU admission, n (%)

1 (5.3%)

2 (11.8%)

0.593

HFNC, n (%)

2 (10.5%)

4 (23.5%)

0.391

Laboratory indicators on admission

   

 Lymphocyte count (* 109/L)

0.9 (0.6, 1.4)

0.9 (0.5, 1.1)

0.633

 D-dimer, mg/L

318 (170, 425)

328 (178, 477)

0.666

 ALT, U/L

26 (19, 53)

22 (15, 27)

0.109

 AST, U/L

22 (18, 41)

19 (17, 21)

0.089

 CRP, mg/L

10.33 (3.55, 27.87)

20.94 (11.39, 68.3)

0.096

 IL-6, pg/mL

13.58 (5.63, 50.46)

14.27 (5.29, 24.01)

0.763

 ESR, mm/h

27 (8, 42)

27 (13, 74)

0.31

 SaO2

98.5% (97.6%, 99.6%)

96.9% (93.7%, 98.3%)

0.004

PFTs at 1-year follow-up#

   

 FVC %

100 (94, 106)

95 (84, 102)

0.096

 FEV1 %

100 (93, 103)

98 (87, 105)

0.579

 PEF

95 (69, 105)

82 (69, 95)

0.168

 FEV1/FVC

82.3 (77.9, 85.1)

82.4 (78.3, 84.7)

0.987

 DLCO %

113 (105, 124)

112 (93, 121)

0.375

 TLC %

107 (96, 111)

94 (83, 99)

0.008

 RV %

132 (121, 144)

105 (95, 120)

< .0001

  1. Kruskal-Wallis test for continuous variables or Fisher’s exact test for categorical variables was used for comparison between groups when applicable with p < 0.05 as significant
  2. The occurrence data are shown as no. (%) unless otherwise indicated. Values indicate no. of positive results/total no. of patients with available assay results
  3. The time data are shown as median data and inter quartile range data in brackets
  4. #Pulmonary function tests were expressed as percent of the predicted value
  5. Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; ALT, Alanine aminotransferase. AST, Aspartate aminotransferase; ESR, Erythrocyte sedimentation rate; CRP, C-reaction protein; IL-6, interleukin-6; SaO2, oxygen saturation; HFNC, high flow nasal catheter oxygen therapy; PFTs, pulmonary function tests; FVC, forced vital capacity; FEV1, forced expiratory volume in the first 1 s of expiration; PEF, peak expiratory flow; DLCO, diffusing capacity of the lung for carbon monoxide; TLC, total lung capacity; RV, residual volume
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us